SK-1405

Drug Profile

SK-1405

Alternative Names: SK 1405

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanwa Kagaku Kenkyusho
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pruritus

Most Recent Events

  • 01 Aug 2017 Phase-II clinical trials in Pruritus in Japan (PO) (NCT03218501)
  • 19 Jul 2017 Sanwa Kagaku Kenkyusho plans a phase II trial for Pruritus (NCT03218501)
  • 01 Jul 2016 Sanwa Kagaku Kenkyusho initiates a phase I pharmacokinetics trial in Healthy volunteers in United Kingdom (PO) (NCT02846181)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top